PACTO: A single center, randomized, phase II study of the combination of nab-paclitaxel and gemcitabine with or without tocilizumab, an IL-6R inhibitor, as first-line treatment in patients with locally advanced or metastatic pancreatic cancer

Line Treatment ◽

Single Center ◽

First Line ◽

Randomized Phase Ii ◽

Capecitabine (X) plus gemcitabine (G) as first-line treatment in patients (pts) with locally advanced/metastatic pancreatic cancer: an open-label, multicenter phase II study

10.1200/jco.2005.23.16_suppl.4141 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 4141-4141 ◽

Cited By ~ 1

Author(s):

H.-S. Song ◽

Y.-R. Do ◽

H.-M. Chang ◽

K.-H. Lee ◽

Y.-H. Kim ◽

...

Keyword(s):

Pancreatic Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Locally Advanced ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Multicenter Phase ◽

Multicenter randomized phase II study comparing alternate-day oral therapy using S-1 with the standard regimen as a first-line treatment for patients with locally advanced and metastatic pancreatic cancer: PAN-01 study.

10.1200/jco.2016.34.15_suppl.4107 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 4107-4107

Author(s):

Masayuki Sho ◽

Atsushi Shimizu ◽

Hiroaki Yanagimoto ◽

Shoji Nakamori ◽

Takuji Okusaka ◽

...

Keyword(s):

Pancreatic Cancer ◽

Phase Ii ◽

Oral Therapy ◽

Phase Ii Study ◽

Locally Advanced ◽

Line Treatment ◽

First Line ◽

Standard Regimen ◽

Randomized Phase Ii ◽

P-036 Phase II study of gemcitabine and curcumin as first line treatment for locally advanced or metastatic pancreatic cancer: preliminary data

Annals of Oncology ◽

10.1093/annonc/mdv233.36 ◽

2015 ◽

Vol 26 ◽

pp. iv10

Author(s):

C. Soldà ◽

R. Bardini ◽

C. Sperti ◽

G. Da Dalt ◽

M. Gion ◽

...

Keyword(s):

Pancreatic Cancer ◽

Phase Ii ◽

Preliminary Data ◽

Phase Ii Study ◽

Locally Advanced ◽

Line Treatment ◽

First Line ◽

Phase II study of Gemcitabine and Curcumin (Meriva®) as first line treatment for locally advanced or metastatic pancreatic cancer: preliminary results

Annals of Oncology ◽

10.1093/annonc/mdv344.41 ◽

2015 ◽

Vol 26 ◽

pp. vi102 ◽

Cited By ~ 1

Author(s):

C. Soldà ◽

R. Bardini ◽

C. Sperti ◽

G. Da Dalt ◽

M. Gion ◽

...

Keyword(s):

Pancreatic Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Locally Advanced ◽

Line Treatment ◽

First Line ◽

Preliminary Results ◽

FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: A randomized phase II trial (PRODIGE 35-PANOPTIMOX).

10.1200/jco.2018.36.15_suppl.4000 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 4000-4000 ◽

Cited By ~ 26

Author(s):

Laetitia Dahan ◽

Jean Marc Phelip ◽

Karine Le Malicot ◽

Nicolas Williet ◽

Jérôme Desrame ◽

...

Keyword(s):

Pancreatic Cancer ◽

Phase Ii ◽

Maintenance Treatment ◽

Phase Ii Trial ◽

Sequential Treatment ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

SWOG S0727: A randomized phase II trial of combination gemcitabine plus erlotinib plus IMC-A12 (cixutumumab) versus gemcitabine plus erlotinib as first-line treatment in patients (pts) with metastatic pancreatic cancer.

10.1200/jco.2010.28.15_suppl.tps223 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. TPS223-TPS223 ◽

Cited By ~ 1

Author(s):

P. A. Philip ◽

B. H. Goldman ◽

R. K. Ramanathan ◽

H. Lenz ◽

A. M. Lowy ◽

...

Keyword(s):

Pancreatic Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial

BMC Cancer ◽

10.1186/s12885-015-1656-4 ◽

2015 ◽

Vol 15 (1) ◽

Cited By ~ 4

Author(s):

Jean-Baptiste Bachet ◽

◽

Benoist Chibaudel ◽

Franck Bonnetain ◽

Pierre Validire ◽

...

Keyword(s):

Pancreatic Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Randomized Phase Ii

A Randomized Phase II Trial of Pemetrexed plus Irinotecan (ALIRI) versus Leucovorin-Modulated 5-FU plus Irinotecan (FOLFIRI) in First-Line Treatment of Locally Advanced or Metastatic Colorectal Cancer

Oncology ◽

10.1159/000120626 ◽

2007 ◽

Vol 73 (1-2) ◽

pp. 9-20 ◽

Cited By ~ 11

Author(s):

Craig Underhill ◽

David Goldstein ◽

Vera A. Gorbounova ◽

Mikhail Y. Biakhov ◽

Igor S. Bazin ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Locally Advanced ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Randomized Phase II Study of PARP Inhibitor Veliparib with Modified FOLFIRI versus FOLFIRI as Second Line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-21-1789 ◽

2021 ◽

pp. clincanres.1789.2021

Author(s):

E. Gabriela Chiorean ◽

Katherine A Guthrie ◽

Philip A Philip ◽

Elizabeth M. Swisher ◽

Florencia Jalikis ◽

...

Keyword(s):

Pancreatic Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Parp Inhibitor ◽

Line Treatment ◽

Second Line ◽

Randomized Phase Ii

Abstract CT101: Final results of a randomized Phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18)

10.1158/1538-7445.am2014-ct101 ◽

2014 ◽

Cited By ~ 23

Author(s):

Richard S. Finn ◽

John P. Crown ◽

Istvan Lang ◽

Katalin Boer ◽

Igor M. Bondarenko ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Advanced Breast ◽

Line Treatment ◽

Cyclin Dependent Kinase ◽

First Line ◽

Randomized Phase Ii ◽